Research programme: CAR-T cell therapies - Fate Therapeitics
Latest Information Update: 22 May 2022
At a glance
- Originator Fate Therapeutics
- Developer Fate Therapeutics; University of Minnesota
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours